Mobility Life: Monitoring Mobility in Daily Lives of People with Neurological Disease

项目摘要 跌倒是受伤、去医院就诊、入住疗养院和降低生活质量的主要原因 患有神经疾病的人。尽管人们一致认为，活动能力受损是大多数跌倒的基础， 在实验室之外评估这些复杂的能力是一种非常ffi的崇拜。做简短的临床检查 不能每天准确地接收fl，在现实生活环境中的功能移动性。有跌倒风险的患者将受益于fit 从一个他们可以轻松使用的系统来测量他们的日常移动性，评估全天的移动性fl功能， 评估他们跌倒的风险，并衡量旨在改善他们功能活动能力的干预措施的效果 并减少他们的跌落。目前还没有商业技术来持续监测移动性或fl的功能 量化正常活动期间自然环境中的跌倒风险。 我们开发并验证了一个名为Mobility Life的不引人注目的系统，以客观地描述步态和 使用可穿戴的惯性传感器在自发活动中转弯。在此第二阶段，我们将制定一项 用于持续监测步态的仪表式脚踝包裹，开发支持临床研究的用户界面， 制定报告，为临床实践显示跌倒风险的迹象，并彻底核实和验证我们的 技术我们还将确定哪些指标最能反映跌倒风险，并确定标准值 对于与预期患者人数相同年龄范围内的非衰退者。我们的特殊fic目标是： 目标一、技术发展：为临床实践准备活动生活。 ·里程碑1：开发用于连续步态监测的仪表式弹性脚踝绷带(SmartSox)。 ·里程碑2：开发有用的临床报告，以传达患者的日常活动障碍、fl功能障碍和 跌倒的风险。 ·里程碑3：完成系统验证和验证，为FDA 510(K)批准做准备，以 市场。 目的II.临床研究：证明活动生活质量监测的临床效用 神经科患者的功能活动和跌倒风险。 ·里程碑4：确定哪些日常生活活动障碍最能预测PD患者或 女士。 ·里程碑5：制定年龄匹配的健康受试者功能活动完整性的参考值。

Project Summary Falls are the leading cause of injuries, hospital visits, nursing home admissions, and reduced quality of life for people with neurological disorders. Although there is consensus that impaired mobility is the basis for most falls, it is very difficult to evaluate these complex abilities outside a laboratory setting. Brief clinical examinations do not accurately reflect daily, functional mobility in real life environments. Patients at risk of falls would benefit from a system they can easily use to measure their daily mobility, assess mobility fluctuations throughout the day, evaluate their risk of falling, and measure effects of interventions aimed at improving their functional mobility and reducing their falls. No commercial technology yet exists to continuously monitor fluctuations in mobility or quantify fall risk in natural environments during normal activities. We developed and validated an unobtrusive system, called Mobility Life, to objectively characterize gait and turning during spontaneous activities with wearable inertial sensors. During this Phase II, we will develop an instrumented ankle wrap for continuous monitoring of gait, develop a user interface to support clinical research, develop reports that show indications of fall risk for clinical practice, and thoroughly verify and validate our technology. We will also determine which metrics are most indicative of fall risk and determine normative values for non-fallers in the same age range as the expected patient populations. Our specific aims are: AIM I. Technology Development: Prepare Mobility Life for clinical practice. · Milestone 1: Develop an instrumented elastic ankle bandage (SmartSox) for continuous gait monitoring. · Milestone 2: Develop useful clinical reports to convey patients' daily mobility impairments, fluctuations, and fall risk. · Milestone 3: Complete the system verification and validation in preparation for FDA 510(k) clearance to market. Aim II. Clinical Research: Demonstrate the clinical utility of Mobility Life to monitor quality of functional mobility and fall risk in neurological patients. · Milestone 4: Determine which daily life mobility impairments best predict fall risk in patients with PD or MS. · Milestone 5: Develop reference values for integrity of functional mobility in healthy age-matched subjects.